Invivogen
Menu

SARS-CoV-2 Spike expressing HEK293 cells

293-SARS2-S Cells Unit size Cat. code Docs Qty Price
SARS-CoV-2 spike (D614)-expressing HEK293 cells
3-7 x 10e6 cells
293-cov2-s
+-
$1,304.00
293-SARS2-S-dfur Cells Unit size Cat. code Docs Qty Price
SARS-CoV-2 spike (D614)-expressing HEK293 cells
3-7 x 10e6 cells
293-cov2-sdf
+-
$1,304.00

Applications of 293-SARS2 Spike Cells
Studying Spike-binding inhibition with InvivoGen's 293-SARS2 Spike Cells

Available upon requestAvailable upon request:

293-SARS2-S-V2-dfur cells (Alpha/B.1.1.7/U.K variant)
293-SARS2-S-V3-dfur cells (Beta/B.1.351/S.A variant)
293-SARS2-S-V5-dfur cells (Gamma/P.1/BRA variant)
293-SARS2-S-V8-dfur cells (Delta/B.1.617.2/IND variant)
293-SARS2-S-V11-dfur cells (Omicron/BA.1 variant)

SARS-CoV-2 Spike (D614)-expressing 293 cells

InvivoGen offers human embryonic kidney (HEK)-293-derived cells, specifically designed for COVID-19 studies:

• 293-SARS2-S Cells: with a functional furin cleavage site and recommended for cell-cell fusion assays with ACE2-expressing cells.

• 293-SARS2-S-dfur Cells: with an inactive furin (dfur) cleavage site facilitating improved surface expression and detection for flow cytometry.

 

They have been engineered to overexpress the original Wuhan‑Hu-1 SARS‑CoV-2 Spike (S) gene, and for optimal expression, the C‑terminal ER-retention signal has been removed [1,2]. Importantly, the Spike protein contains a furin cleavage site that can affect its cellular expression [3].

More More details

 

A crucial step in developing successful COVID-19 treatments is the validation of their efficacy using rapid, reliable and robust platforms. To this end, cell-based assays using Spike-expressing cells provide a more relevant in vivo biological context than biochemical assays (e.g. ELISAs). 

 

Key Features

  • Stable expression of the original SARS-CoV-2 Spike (D614) protein.
  • Functionally validated in cell fusion assays with HEK-Blue™ hACE2(-TMPRSS2) Cells (293-SARS2-S Cells) and by flow cytometry (293-SARS2-S-dfur Cells).

Applications

  • 293-SARS2-S-dfur Cells: Screening patient/vaccinated sera and/or monoclonal antibodies against the SARS-CoV-2 Spike by flow cytometry.
  • 293-SARS2-S Cells: Cell fusion assays for screening novel inhibitors of the SARS-CoV-2 Spike-host interaction using InvivoGen's permissive reporter cell lines (HEK-Blue™ hACE2(-TMPRSS2) and A549-Dual™ hACE2-TMPRSS2).

 

Learn more about InvivoGen's tools for cell fusion assays

 

293-SARS2-S-dfur cells have also been generated with the Spike of other variants of concern: Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1).
These cells have been used to compare the activity of anti-SARS-CoV-2 Spike antibodies.
See data

 

References:

1. Johnson, M.C. et al. 2020. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. J Virol 94.
2. Ou, X. et al. 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun 11, 1620.
3. Coutard, B. et al. 2020. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res 176, 104742.

Figures

Cell fusion with 293-SARS-S cells
Cell fusion with 293-SARS-S cells

Figure 1 - Measuring fusion of 293 Spike-expressing cells and HEK-Blue™ hACE2 cells. 293-SARS2-S-dfur and 293-SARS2-S cells were transiently transfected with a MyD88 expression plasmid (pUNO1-hMyD88) using LyoVec™. After 24 hours, the cells were washed, and a dilution series was co‑cultured with either 2.5 x104 HEK-Blue™ Null1-v or HEK‑Blue™ hACE2 cells. After overnight incubation, cell fusion was assessed by measuring the activity of SEAP in the supernatant using QUANTI-Blue™ Solution, a SEAP detection reagent. Data are presented as OD630nm

Spike detection in 293-SARS2-S-dfur Cells by flow cytometry
Spike detection in 293-SARS2-S-dfur Cells by flow cytometry

Figure 2 - Validation of the expression of SARS-CoV-2 spike by 293-SARS2-S‑dfur cells. 293 parental (orange), 293-SARS2-S (blue), and 293-SARS2-S-dfur (red) cells were incubated with Anti‑CoV2RBD‑c2-hIgG1 (clone B38) for 1h at 4°C. Cells were then washed and incubated with goat anti-human IgG-FC coupled to PE for 1h at 4°C. Cell surface staining was analyzed by flow cytometry.

Back to the top

Specifications

Growth medium: DMEM, 4.5 g/L glucose, 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal bovine serum (FBS), 100 U/ml penicillin, 100 µg/ml streptomycin, 100 µg/ml Normocin™

Antibiotic resistance: Blasticidin

Quality Control:

  • SARS-CoV-2 Spike gene expression has been verified by RT-PCR, flow cytometry, and/or functional fusion assays.
  • The stability for 20 passages, following thawing, has been verified for both cell lines.
  • These cells are guaranteed mycoplasma-free. 

InvivoGen's products are covered by a Limited Use License (See Terms and Conditions).

Back to the top

Contents

Please note: Each cell line is sold separately. See TDS for the exact contents of each cell line.

  • 3-7 x 106 293-SARS2-S cells or 293-SARS2-S-dfur in a cryovial or shipping flask.
  • 1 ml of Blasticidin (10 mg/ml). Store at 4 °C or at -20 °C.
  • 1 ml of Normocin™ (50 mg/ml). Normocin™ is a formulation of three antibiotics active against mycoplasmas, bacteria, and fungi. Store at -20 °C.

IMPORTANT: If cells are shipped frozen (i.e. in a cryovial) and are not frozen upon arrival, contact InvivoGen immediately.

Shipped on dry ice Shipped on dry ice (Europe, USA, Canada and some areas in Asia)

Back to the top

Details

SARS-CoV-2 Spike

Spike (S) is a structural glycoprotein expressed on the surface of SARS‑CoV-2. It mediates membrane fusion and viral entry into target cells upon binding to the host receptor, ACE2 and host proteolytic cleavage (e.g. TMPRSS2 and furin). The S protein consists of an N-terminal ectodomain, a transmembrane anchor, and a short C-terminal cytoplasmic tail. The ectodomain contains the S1 subunit, which encodes the receptor-binding domain (RBD), a key target in treatment and vaccination strategies against COVID-19, as well as the S2 subunit, needed for membrane fusion. Notably, the C-terminal cytoplasmic tail of the S protein encodes a presumptive endoplasmic reticulum (ER)-retention motif (KxHxx), which has previously been shown to enable the accumulation of SARS-CoV S proteins at the ER-Golgi intermediate compartment (ERGIC) and facilitate their incorporation into new virions.

Learn more about the SARS-CoV-2 Spike protein.

Back to the top

FAQ Cell Lines

Visit our FAQ Any questions about our cell lines ? Visit our frequently asked questions page

Back to the top

Citations

Customer Service
& Technical Support
Shopping cart is empty